| Aug 8 |
Allogene (ALLO) Posts Narrower Than Expected Loss in Q2
|
| Aug 8 |
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
|
| Aug 8 |
7 Biotech Stocks to Buy for Their Game-Changing Potential
|
| Aug 7 |
Allogene Therapeutics Non-GAAP EPS of -$0.35 in-line
|
| Aug 7 |
Allogene Therapeutics: Q2 Earnings Snapshot
|
| Aug 7 |
Allogene Therapeutics Reports Second Quarter 2024 Financial Results and Business Update
|
| Aug 6 |
Allogene Therapeutics Q2 2024 Earnings Preview
|
| Jul 31 |
Allogene Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update
|
| Jul 1 |
Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene Ansegedleucel (cema-cel) as First Line (1L) Consolidation Treatment for Patients with Large B-Cell Lymphoma (LBCL)
|
| Jun 27 |
With 56% institutional ownership, Allogene Therapeutics, Inc. (NASDAQ:ALLO) is a favorite amongst the big guns
|
